Literature DB >> 21900221

Myeloid growth factors.

Jeffrey Crawford1, Jeffrey Allen, James Armitage, Douglas W Blayney, Spero R Cataland, Mark L Heaney, Sally Htoy, Susan Hudock, Dwight D Kloth, David J Kuter, Gary H Lyman, Brandon McMahon, David P Steensma, Saroj Vadhan-Raj, Peter Westervelt, Michael Westmoreland.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21900221     DOI： 10.6004/jnccn.2011.0075

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN： 1540-1405            Impact factor:   11.908


× No keyword cloud information.
  18 in total

Review 1.  A way forward on the medically appropriate use of white cell growth factors.

Authors:  Thomas J Smith; Bruce E Hillner
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

2.  Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) guideline for prophylaxis with granulocyte colony-stimulating factors (G-CSF) in gynecologic malignancies, including breast cancer.

Authors:  Edgar Petru; Alain Gustave Zeimet; Paul Sevelda; Michael Seifert; Christian Singer; Michael Hubalek; Lukas Angleitner-Boubenizek; Paul Speiser; Christoph Benedicic; Wolfgang Stummvoll; Alexander Reinthaller
Journal:  Wien Klin Wochenschr       Date:  2012-06-28       Impact factor: 1.704

Review 3.  Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.

Authors:  Bradford R Hirsch; Gary H Lyman
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

4.  Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.

Authors:  Jean Paul Salmon; Martin Smakal; Charisios Karanikiotis; Marek Z Wojtukiewicz; Yohann Omnes; Lucy DeCosta; Sally Wetten; James O'Kelly
Journal:  Support Care Cancer       Date:  2018-09-26       Impact factor: 3.603

Review 5.  Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.

Authors:  Alena M Pfeil; Kim Allcott; Ruth Pettengell; Gunter von Minckwitz; Matthias Schwenkglenks; Zsolt Szabo
Journal:  Support Care Cancer       Date:  2014-10-07       Impact factor: 3.603

6.  Predictive factors for severe and febrile neutropenia during docetaxel chemotherapy for castration-resistant prostate cancer.

Authors:  Keisuke Shigeta; Takeo Kosaka; Satoshi Yazawa; Yota Yasumizu; Ryuichi Mizuno; Hirohiko Nagata; Kazunobu Shinoda; Shinya Morita; Akira Miyajima; Eiji Kikuchi; Ken Nakagawa; Shintaro Hasegawa; Mototsugu Oya
Journal:  Int J Clin Oncol       Date:  2014-09-09       Impact factor: 3.402

Review 7.  Comparison of pegfilgrastim prescribing practice to national guidelines at a university hospital outpatient oncology clinic.

Authors:  Geralyn E Waters; Patricia Corrigan; Mandy Gatesman; Thomas J Smith
Journal:  J Oncol Pract       Date:  2012-11-06       Impact factor: 3.840

Review 8.  The impact of the granulocyte colony-stimulating factor on chemotherapy dose intensity and cancer survival: a systematic review and meta-analysis of randomized controlled trials.

Authors:  G H Lyman; D C Dale; E Culakova; M S Poniewierski; D A Wolff; N M Kuderer; M Huang; J Crawford
Journal:  Ann Oncol       Date:  2013-06-20       Impact factor: 32.976

Review 9.  Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Authors:  S Neumann; S W Krause; G Maschmeyer; X Schiel; M von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2013-02-15       Impact factor: 3.673

10.  Supportive therapy in medical therapy of head and neck tumors.

Authors:  Hartmut Link
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.